NORML Formally Responds to DEA’s Proposed Changes to Marijuana Cultivation Rules

NORML Formally Responds to DEA’s Proposed Changes to Marijuana Cultivation Rules

The National Organization for the Reform of Marijuana Laws (NORML) has formally submitted comments to the US Federal Register opposing the Drug Enforcement Administration’s proposed rule changes governing the federal production and distribution of cannabis for clinical research purposes. Under existing regulations, the agency only licenses one facility — the University of Mississippi — to cultivate cannabis for use in FDA-approved clinical trials. Researchers have consistently criticized the poor quality of these plants, which they say fail to accurately reflect the varieties of marijuana commercially available in the United States. As a result, the DEA has been encouraged for over a decade to expand the pool of federally licensed cannabis producers — a move that the agency has largely resisted. In 2016, the agency appeared to reconsider its longstanding policy, and publicly stated for the first time that it would consider additional applicants. To date, however, the DEA has failed to either affirm or reject any of the more than 30 applications it has received. Under the proposed rules issued by the DEA on March 23, the agency continues to maintain sole discretion to decide which applicants, if any, will be permitted to grow cannabis for research purposes, and it provides no timeline under which the DEA must act on the numerous applications already before it. In its response to the DEA’s proposed changes, NORML writes: “While NORML has long supported facilitating and expanding domestic clinical research efforts, we do not believe that these proposed rules, if enacted, will achieve…

Excerpt only …
READ MORE BELOW
Source : norml
Link to original : NORML Formally Responds to DEA’s Proposed Changes to Marijuana Cultivation Rules
reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.